Study of Efficacy of BZ019 in Large B-cell Lymphoma
This is a single arm,open-label, non-randomized phase 2 study to determine the efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.
Large B-cell Lymphoma
BIOLOGICAL: BZ019
Objective response rate (ORR), Clinical response will be assessed by RECIST 1.1., Month 3
Pharmacokinetics (PK), Peak Plasma Concentration (Cmax), Month 12|Pharmacodynamics (PD), PD of IL-2, IL-4, IL-6,IL-10, IL-15, IFN-γ, TNF-α will be analysed after CAR T cell infusion, Month 12|Quality of life（QOL）, Quality of life will be assessed by EQ-5D health Index scale, Month 12
This is a single arm,open-label, non-randomized phase 2 study to determine the efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.